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Introduction
Endoscopic sphincterotomy (EST) is the current standard pro-
cedure for removal of bile duct stones during endoscopic retro-
grade cholangiopancreatography (ERCP) [1] but is associated
with adverse events such as bleeding and perforation, which
can be serious [2]. Endoscopic papillary balloon dilation
(EPBD) was first reported in 1983 as an alternative to EST [3].
Although EPBD has been shown to have similar effectiveness
for small stones, it is not widely used because of the high risk
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ABSTRACT
Background and study aims Endoscopic papillary bal-
loon dilation (EPBD) is a method of bile duct stone removal
that has a better long-term outcome but a high risk of post-
ERCP pancreatitis (PEP). Recent studies have suggested that
5-minute EPBD can reduce the incidence of PEP. This study
aimed to examine the safety and effectiveness of longer
duration EPBD compared with shorter duration EPBD (5
minutes vs. 15 seconds after disappearance of the waist of
a dilation catheter).
Patients and methods Patients without a history of endo-
scopic sphincterotomy or EPBD who underwent EPBD to re-
move bile duct stones were selected retrospectively from
five centers. The incidence of PEP, other early adverse
events, and outcomes of EPBD were compared between
the groups. A multivariable analysis of risk factors for PEP
was performed.
Results A total of 607 patients (157 and 450 in the 5-min-
ute and 15-second EPBD groups, respectively) were includ-
ed. There were no statistically significant differences be-
tween the groups in terms of the incidence of PEP (8.3%
and 8.9% in the 5-minute and 15-second EPBD groups,
respectively; P=0.871) and the incidence of overall early
adverse events (P=0.999). Although 5-minute EPBD elon-
gated the procedure time (45 vs. 37 minutes, P<0.001), it
increased the rate of complete stone removal during a sin-
gle session (P <0.001) and decreased the use of lithotripsy
(P <0.001).
Conclusions Compared with 15-second EPBD, 5-minute
EPBD did not reduce the incidence of PEP.
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of post-ERCP pancreatitis (PEP) [4–9]. EPBD is now performed
only in patients with a high risk of post-EST bleeding, such as
those with liver cirrhosis, those on dialysis, or those taking an-
tithrombotic agents [10–13]. Recently, improved long-term
outcomes after EPBD cast light on this procedure once again.
EPBD has been reported to reduce the incidence of bile duct
stone recurrence, cholangitis, and cholecystitis compared with
EST [14, 15], presumably due to preserved sphincter of Oddi
function and prevention of resultant continuous duodenobili-
ary reflux [16–18].
EPBD not only has a good long-term outcome, it can also
help to reduce the incidence of PEP by changing the duration
of EPBD. A recent randomized controlled trial (RCT) and subse-
quent meta-analysis suggested that 5-minute EPBD might re-
duce the risk of PEP to as low as that for EST [19, 20]; however,
our previous data suggested that 15-second EPBD was associat-
ed with a lower incidence of PEP compared with 2-minute
EPBD, although this discrepancy could be due to different pres-
sure applications [21–23]. Despite the potential effectiveness
of 15-second EPBD suggested in our previous study, a RCT and
meta-analysis have implicated the effectiveness of quite long
duration EPBD (5-minute EPBD). Therefore, there is a great
need to evaluate our conventional 15-second EPBD and 5-min-
ute EPBD. The current study was performed to evaluate the
safety and effectiveness of 5-minute EPBD for bile duct stone
removal compared with conventional 15-second EPBD.
Patients and methods
Study design
This multicenter retrospective study was performed to evaluate
the safety and effectiveness of 5-minute EPBD for endoscopic
removal of bile duct stones compared with 15-second EPBD.
PEP risk factors were evaluated using univariable and multivari-
able analyses.
Written informed consent for the procedure and use of data
was obtained from each patient in accordance with the Declara-
tion of Helsinki. This study was approved by the institutional re-
view board in each institution.
Study outcomes
The primary end point of this study was the incidence of PEP
associated with EPBD. Secondary end points included early
(within 30 days of the procedure) adverse events and effective-
ness of EPBD for stone removal indicated by the technical suc-
cess of EPBD, successful complete stone removal during a sin-
gle session, use of lithotripsy, and procedure duration during
the first session.
Adverse events associated with ERCP were defined and grad-
ed according to the American Society for Gastrointestinal
Endoscopy lexicon for endoscopic adverse events [24]. PEP
was defined as abdominal pain along with an increase in serum
amylase levels of more than threefold the upper limit of the
normal range at each institution. All patients were hospitalized
at least one night, and blood tests were performed routinely
18–24 hours after the procedure. We performed computed to-
mography for all those cases to evaluate the presence and de-
gree of inflammation of the pancreas. The severity of PEP was
graded as follows: mild, requiring fasting and treatment for ≤3
days; moderate, requiring fasting and treatment for 4 to 10
days; and severe, requiring fasting and treatment for > 10 days,
admission to the intensive care unit for > 1 night, or surgical in-
tervention.
Patients
Data were collected for consecutive patients who underwent
EPBD to remove bile duct stones at one academic center and
four affiliated hospitals between July 2008 and September
2014.Our previous study [22] has shown that 2-minute EPBD
appears to be associated with a higher risk of PEP compared
with 15-second EPBD. Therefore, from July 2008 until June
2013, 15-second EPBD was performed. When the RCT was re-
ported [20], we introduced 5-minute EPBD into clinical prac-
tice from July 2013. Exclusion criteria were as follows: (1) a his-
tory of EST or EPBD, (2) precut sphincterotomy or EST com-
bined with EPBD, (3) large balloon dilation (balloon diameter
> 10mm), (4) active pancreatitis at the time of EPBD, and (5)
altered surgical anatomy with Roux-en-Y or Billroth-II recon-
structions.
Procedure and techniques
A side-viewing duodenoscope (JF-240, JF-260V, or TJF-260V;
Olympus, Tokyo, Japan) was inserted under moderate sedation
using intravenous diazepam and pethidine hydrochloride or
pentazocine hydrochloride. Wire-guided cannulation (WGC)
was attempted under fluoroscopic guidance using a cannula
(ERCP catheter; MTW Endoskopie, Wesel, Germany) or a sphinc-
terotome (CleverCut3; Olympus or Autotome; Boston Scientific
Japan, Tokyo, Japan) with a 0.035-inch standard guidewire (Re-
voWave; Piolax, Kanagawa, Japan or Jagwire; Boston Scientific
Japan) or a 0.035-inch hydrophilic guidewire (Radifocus; Teru-
mo, Tokyo, Japan). During the WGC, a guidewire was manipula-
ted by an assistant physician with expertise in ERCP. Contrast in-
jection was performed after several attempts at WGC at the
discretion of endoscopists. After selective biliary cannulation
was achieved, we performed a cholangiogram to confirm the
bile duct stones and measure the bile duct diameter. The short-
est diameter of the largest stone was recorded as the stone di-
ameter, assuming that stones could be removed by prudent
procedures if the shortest diameter was smaller than the diam-
eter of the lower bile duct. A balloon catheter (Hurricane RX;
Boston Scientific Japan) matched to the diameter of the lower
bile duct (≤10mm) was positioned across the papilla and infla-
ted gradually (0.5 atmospheres per ~15 seconds) under fluoro-
scopic guidance until the waist of the balloon disappeared.
After the waist had disappeared, the balloon pressure was
maintained for 15 seconds or 5 minutes, and deflated immedi-
ately after that. If the waist of the balloon did not disappear
after EPBD, balloon dilation was not added considering the in-
creased risk of perforation and pancreatitis. EPBD was per-
formed only during the first ERCP session.
Stones were removed using a 4-wire or 8-wire basket cathe-
ter and/or a retrieval balloon catheter. If the stone diameter
was larger than 10mm or the size of an EPBD balloon, endo-
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scopic mechanical lithotripsy (EML) was performed. In addition,
we used EML when stone removal was not completed using a
basket catheter. If the stones could not be fragmented success-
fully via EML, extracorporeal shock wave lithotripsy or electro-
hydraulic lithotripsy was performed in subsequent sessions.
Each session was capped at approximately 60 minutes, after
which an additional procedure was scheduled to reduce the
risk of adverse events. Complete stone removal was confirmed
by intraductal ultrasound sonography or cholangiogram using a
retrieval balloon catheter. Prophylactic pancreatic stents were
not used routinely. The procedure time was considered to be
the time from insertion to withdrawal of the duodenoscope.
ERCP procedures including biliary cannulation, EPBD, and stone
removal were performed in a consistent manner across the cen-
ters. All patients were hospitalized for at least one night after
the procedure. The definition of trainees was endoscopists
whose experience was less than 4 years [25], and difficult can-
nulation was 10 attempts or 10 minutes.
Statistical analysis
The incidence of PEP with 15-second EPBD was approximately
10% in our institutions in recent years [26]. In contrast, the pre-
vious RCT and meta-analysis reported that a long duration of
EPBD decreased the incidence of PEP by almost one-third com-
pared with short duration EPBD [19, 20]. In the meta-analysis,
the odds ratio of PEP for short duration EPBD compared with
long duration EPBD was 3.56–3.85. Assuming the incidence of
PEP with 5-minute EPBD was 2.8%, the estimated sample size
was 134 cases for the 5-minute EPBD group and 402 cases for
the 15-minute EPBD respectively (α=0.05, power =0.80, sam-
ple size ratio was 1:3).
The chi-squared test or Fisher’s exact test was used to eval-
uate univariable PEP risk factors. We used a multivariable logis-
tic regression model to adjust for potential confounders includ-
ing younger age, pancreatic duct opacification, and pancreatic
stent [20, 27–29].
Continuous variables were expressed as medians and inter-
quartile ranges and categorical variables as numbers and per-
centages of patients. Continuous variables were compared
using the Wilcoxon rank sum test, and categorical variables
were compared using the chi-squared test or Fisher’s exact
test, as appropriate.
All statistical analyses were performed using R software, ver-
sion 3.2.3 (R Development Core Team: http://www.r-project.
org). A two-sided P value <0.05 was considered statistically sig-
nificant in all analyses.
Results
Patients
A total of 716 patients who underwent EPBD for bile duct
stone removal were identified. Fifty patients with a history of
Roux-en-Y or Billroth-II reconstructions and 79 patients who
received endoscopic papillary large balloon dilation were ex-
cluded, leaving 607 patients in the study cohort; 157 and 450
cases underwent 5-minute EPBD and 15-second EPBD, respec-
tively (▶Fig. 1).
The baseline characteristics of the patients are shown in
▶Table1. There were statistically significant differences be-
tween the groups in the stone diameter and number of stones
(5.0 vs. 6.0mm, P=0.005 and 1 vs. 2, P=0.050, in the 5-minute
vs. 15-second EPBD group, respectively). The median diameter
of the lower bile duct was statistically smaller in the 5-minute
EPBD group compared with the 15-second EPBD group (9.0 vs.
10.0mm, P<0.001).
Stone removal
The technical success of EPBD was achieved in all 607 patients
in the 5-minute and 15-second EPBD groups. The outcomes of
EPBD are shown in ▶Table 2. The rate of complete stone re-
moval during a single session was statistically significantly high-
er in the 5-minute EPBD group (86.0% vs. 72.7%, P<0.001, re-
lative effect size = 13.3% (95%CI, 6.5–20.1%)). In a subgroup a-
nalysis limited to the cases where the stone diameter was smal-
ler than the EPBD balloon diameter, 5-minute EPBD was not
associated with a higher rate of complete stone removal during
a single session (P=0.206). Although there were no statistically
significant differences in the rate of overall complete stone re-
moval, more ERCP sessions were required in the 15-second
EPBD group (P=0.002). Lithotripsy was performed in 8.3% of
patients in the 5-minute EPBD group and in 20.0% in the 15-
second EPBD group (P<0.001, relative effect size =–11.7% [95
%CI,–17.4 to –6.0%]). The median procedure time during the
first session was statistically significantly longer in the 5-minute
EPBD group than in the 15-second EPBD group (45.0 vs. 37.0
minutes, P<0.001). However, this statistically significant differ-
ence disappeared after excluding the ballooning time from the
procedure time (40.0 vs. 36.7 minutes, P=0.412).
109 were excluded
 50 patients with 
  Roux-en-Y or 
  Billroth-II reconstructions
 79 patients with large 
  balloon dilation
716 patients with bile duct stones without the 
history of EST or EPBD from July 2008 to Sept. 2014
607 patients were eligible for the analysis
450 was performed 
15-second EPBD
 from July 2008 
to June 2013
157 was performed 
5-minute EPBD
 from July 2013 
to Sept. 2014
▶ Fig. 1 Flowchart of patient selection into the 5-minute and
15-second EPBD groups for removal of bile duct stones. EPBD,
endoscopic papillary balloon dilation; EST, endoscopic sphincter-
otomy.
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The details of the stone removal procedures are summarized
in ▶Table 3. The rates of PEP risk factors such as pancreatic
duct opacification [27], accidental guidewire insertion into the
pancreatic duct [30, 31], difficult cannulation [28], and place-
ment of prophylactic pancreatic stent [29, 32] were not differ-
ent between the groups. However, the administration of non-
steroidal anti-inflammatory drugs (NSAIDs) [33] and trainee in-
volvement in the procedure [34] were statistically significantly
higher in the 5-minute EPBD group compared with the 15-sec-
ond EPBD group (36.8% vs. 1.3%, P<0.001 and 70.4% vs.
51.2 %, P <0.001, respectively).
▶ Table 1 Baseline characteristics of the 5-minute and 15-second EPBD for removal of bile duct stones.
5-minute EPBD
(n=157)
15-second EPBD
(n=450)
P value
Sex, male/female 106/51 (67.5/32.5) 272/178 (60.4/39.6) 0.126
Age, years 75 (26– 99, 64–81) 73.5 (10–100, 64– 81) 0.510
ASA-PS, 1/2/3/4 32/90/35/0
(20.4/57.3/22.3)
140/236/71/3
(31.1/52.4/15.8/0.7)
0.027
Periampullary diverticulum 49 (31.2) 182 (40.4) 0.045
Gallbladder stone 116 (73.9) 274 (60.9) 0.004
Previous cholecystectomy 17 (10.8) 60 (13.3) 0.487
Stone diameter, mm 5 (1–20, 4 –7) 6 (1–36, 4–9) 0.005
Number of stones 1 (1–20, 1 –3) 2 (1–36, 1–3) 0.050
Bile duct diameter, mm 9 (4–20, 8 –11) 10 (3 –28, 8 –12) < 0.001
Dilation balloon diameter,
4/6/8/10mm
2/37/85/33
(1.3/23.6/54.2/21.0)
3/74/318/55
(0.7/16.4/70.7/12.2)
< 0.001
Peak pressure of the balloon, atmospheres 2 (0.5–7, 2–3) 3 (1–8, 2–4) < 0.001
Data are expressed as numbers and percentages of patients within a given group or as medians (range, interquartile range). ASA-PS, American Society of Anesthe-
siologists Physical Status Classification System score; EPBD, endoscopic papillary balloon dilation.
▶ Table 2 Outcomes of the 5-minute and 15-second EPBD groups.
5-minute EPBD
(n=157)
15-second EPBD
(n=450)
P value
Use of lithotripsy 13 (8.3) 90 (20.0) < 0.001
▪ EML 13 (8.3) 89 (19.8) < 0.001
▪ ESWL 1 (0.6) 2 (0.4)
▪ EHL 1 (0.6) 1 (0.2)
Procedure time during the first session, minutes 45.0 (18.0–132, 35.0 –57.0) 37.0 (10.0– 114, 30.0–50.0) < 0.001
Procedure time excluding balloon time, minutes 40.0 (13.0–127, 30.0 –52.0) 36.7 (9.7–114, 29.7–49.7) 0.412
Complete stone removal during a single session 135 (86.0) 327 (72.7) < 0.001
Overall complete stone removal 156 (99.4) 438 (97.3) 0.201
Number of ERCP sessions1 0.002
▪ 1 135 (86.0) 333 (74.0)
▪ 2 19 (12.1) 100 (22.2)
▪ ≥3 3 (1.9) 17 (3.8)
Data are expressed as numbers and percentages of patients within a given group or as medians (range, interquartile range). EHL, electrohydraulic lithotripsy; EML,
endoscopic mechanical lithotripsy; EPBD, endoscopic papillary balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; ESWL, extra shock wave
lithotripsy.
1 The Wilcoxon rank sum test was used to estimate differences in the number of ERCP sessions between the groups.
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PEP and other early adverse events
Early adverse events are shown in▶Table4. There was no statis-
tically significant difference in terms of the incidence of PEP
(8.3% and 8.9% in the 5-minute and 15-second EPBD groups,
respectively; P=0.871, relative effect size =–0.6% (95%CI,–5.7
to 4.4%)), and the incidences of severe PEP (1.9% and 0.4%,
respectively; P=0.112, relative effect size =1.5% (95%CI,–0.8
to 3.7%)). The association between PEP and EPBD groups did
not alter materially after adjustment for multiple potential con-
founders including younger age, pancreatic duct opacification,
and pancreatic stent (▶Table 5 and▶Table 6). In a secondary a-
nalysis limited to patients who did not receive NSAIDs or a pan-
creatic stent, we did not find a statistically significant differ-
ence. The incidence of PEP was 7.4% in the 5-minute EPBD
group and 7.6% in the 15-second EPBD group, respectively (P=
0.999). However, the incidence of PEP tended to be higher in the
15-second EPBD group in patients who received NSAIDs or a
pancreatic stent (9.7% vs 18.5%, P=0.188). All patients with
PEP were managed conservatively without the need for further
interventions. The overall rate of early adverse events was not
different between the groups (13.4% and 13.1% in the 5-minute
and 15-second EPBD groups, respectively; P=0.999). Moderate
bleeding was observed in one patient (0.2%) in the 15-second
EPBD group.One patient in each group developed retroperito-
neal perforation, but this was managed conservatively.
Discussion
This retrospective cohort study was performed to evaluate the
safety and effectiveness of 5-minute EPBD compared with 15-
second EPBD for bile duct stone removal. In this study, 5-min-
ute EPBD did not reduce PEP, in contrast to previous reports
[19, 20], or the overall incidence of early adverse events. The
use of lithotripsy was reduced and the prospect of complete
stone removal in a single session was improved after 5-minute
EPBD. The procedure time was 8 minutes longer in the 5-min-
ute EPBD group than in the 15-second EPBD group.
We did not find a statistically significant difference in the in-
cidence of PEP between the 5-minute and 15-second EPBD
groups (8.3% vs. 8.9%, P=0.871). Although the multivariable a-
nalysis revealed pancreatic opacification as a risk factor for PEP,
there was no relationship between PEP and the EPBD groups, in
this study. However, accumulating evidence indicates that a
longer duration of EPBD can reduce the incidence of PEP. In a
RCT of 5-minute vs. 1-minute EPBD [20], the incidence of PEP
was statistically significantly lower in the 5-minute EPBD group
than in the 1-minute EPBD group (4.8% vs. 15.1%; P=0.038).
The investigators speculated that adequate dilation of the pa-
pilla via EPBD over a longer duration could facilitate subsequent
stone removal procedures and mitigate damage to the ampulla.
Based on this RCT, a subsequent meta-analysis comparing EPBD
and EST showed superiority of long duration over short dura-
tion EPBD and even over EST in terms of early adverse events
[19]. Despite these promising results, we failed to demonstrate
the superiority of 5-minute EPBD in terms of PEP. A trend to-
ward a lower incidence of PEP in the 5-minute EPBD group
among patients who received a pancreatic stent or NSAIDs
may suggest the potential effectiveness of 5-minute EPBD in
prevention of PEP in high risk patients, but statistical power
was limited.
In the previous RCT, a 10-mm EPBD balloon was used in all
cases contrary to our study in which the size of dilation balloon
was matched to the lower bile duct [20]. Although the low-de-
gree dilation of the biliary orifice using a smaller balloon cathe-
▶ Table 3 Procedures in the 5-minute and 15-second EPBD groups.
5-minute EPBD
(n=157)
15-second EPBD
(n=450)
P value
Pancreatic duct opacification 17 (10.9) 62 (13.8) 0.409
Main pancreatic duct/
first pancreatic branches/
second pancreatic branches/
acinarization
10/7/0/0
(6.4/4.5/0/0)
24/29/6/3
(5.3/6.5/1.3/0.7)
0.498
Guidewire insertion into the pancreatic duct1 63 (41.7) 154 (40.5) 0.845
Number of guidewire insertions into the pancreatic duct
(in cases of guidewire insertion)1
2 (1 –10, 1 –5) 2 (1–40, 1–4) 0.722
Difficult cannulation
(≥10 times or≥10 minutes)1
34 (23.3) 105 (26.4) 0.507
ERCP performed by trainees 107 (70.4) 230 (51.2) < 0.001
NSAIDs 56 (36.8) 6 (1.3) < 0.001
Pancreatic stent 11 (7.2) 48 (10.7) 0.270
Data are expressed as numbers and percentages of patients within a given group or as medians (range, interquartile range). EPBD, endoscopic papillary balloon
dilation; ERCP, endoscopic retrograde cholangiopancreatography; NSAIDs, nonsteroidal anti-inflammatory drugs.
1 Data on 76 guidewire insertions into the pancreatic duct (6 in 5-minute EPBD group and 70 in 15-second EPBD group, respectively) and 63 difficult cannulations
(11 in 5-minute EPBD group and 52 in 15-second EPBD group, respectively) were missing.
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▶ Table 4 Short-term adverse events in the 5-minute and 15-second EPBD groups.
5-minute EPBD
(n=157)
15-second EPBD
(n=450)
P value
Overall 21 (13.4) 59 (13.1) 0.999
Pancreatitis1 13 (8.3) 40 (8.9) 0.871
▪ Mild/moderate/severe 10/0/3
(6.4/0/1.9)
29/9/2
(6.4/2.0/0.4)
0.091
Cholangitis 4 (2.5) 14 (3.1) 0.999
Cholecystitis 5 (3.2) 4 (0.9) 0.543
Aspiration pneumonia 1 (0.6) 4 (0.9) 0.999
Liver abscess 1 (0.6) 1 (0.2) 0.451
Bleeding 0 1 (0.2) 0.999
Retroperitoneal perforation 1 (0.6) 1 (0.2) 0.451
Basket impaction 0 0 NA
Data are expressed as numbers and percentages of patients within a given group. EPBD, endoscopic papillary balloon dilation; NA, not available.
1 We included PEP associated with the first ERCP session only, as a study outcome.
▶ Table 5 Univariable analysis of risk factors for PEP.
Univariable
OR 95%CI P value
Younger age (< 50 y) 1.07 0.32–2.87 0.803
Female sex 1.41 0.76–2.58 0.239
Periampullary diverticulum 1.17 0.63–2.15 0.657
Bile duct diameter < 10mm 1.12 0.61–2.05 0.773
Stone diameter > 10mm 1.19 0.43–2.80 0.654
Number of stones > 3 1.97 1.00–3.76 0.033
Dilation balloon diameter < 10mm 0.81 0.37–1.97 0.545
Peak pressure of the balloon >4 atmospheres 0.66 0.13–2.16 0.608
5-minute EPBD 0.93 0.44–1.83 0.871
Procedure time <30 minutes 0.82 0.35–1.71 0.728
Lithotripsy 1.00 0.42–2.17 0.999
Complete stone removal during a single session 0.97 0.49–2.04 0.999
ERCP performed by trainees 1.45 0.78–2.76 0.247
Difficult cannulation (≥10 times or≥10 minutes) 1.91 0.98–3.63 0.041
Pancreatic duct opacification 3.01 1.45–5.98 0.002
Guidewire insertion into the pancreatic duct 2.11 1.14–3.96 0.012
Number of guidewire insertions into the pancreatic duct > 3 times 2.06 0.72–5.14 0.104
NSAIDs 1.12 0.38–2.80 0.812
Pancreatic stent 2.36 0.99–5.15 0.029
CI, confidence interval; EPBD, endoscopic papillary balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; NSAIDs, nonsteroidal anti-inflamma-
tory drugs; OR, odds ratio; PEP, post-ERCP pancreatitis.
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ter might have driven our findings toward null, the diameter of
a dilation balloon catheter was not associated with a higher in-
cidence of PEP in our univariable analysis. Nonetheless, a fur-
ther investigation using endoscopic papillary large balloon dila-
tion with a >12-mm balloon is warranted. We also thought that
the cause of PEP after EPBD is attributed to damage to the am-
pulla, and which was mainly caused by stone extraction through
the narrow opening after EPBD. To date, we have sought the
usefulness of EPBD for stone extraction and are familiar with
the stone extraction procedure after EPBD: gentle stone extrac-
tion along the distal bile duct axis, the use of EML for large
stones, and shortening the procedure duration to reduce ex-
cessive damage to the papilla [21–23]. Hence, the superiority
of 5-minute EPBD in terms of PEP might have been attenuated
by these experiences, but the relatively wide opening after 5-
minute EPBD can be helpful to those endoscopists who are ac-
customed to EST only.
Regarding the effectiveness of the procedure, the incidence
of complete stone removal during a single session was higher
and the use of lithotripsy was lower in the 5-minute EPBD
group.However, owing to the chronological aspect of our EPBD
database, cases of large andmultiple stones, which were eligible
for large balloon dilation in recent years, were contained in the
15-second EPBD group. The differences in those baseline char-
acteristics influenced the preferable effectiveness of the 5-min-
ute EPBD group in this study. As shown in our previous study on
10-mm EPBD [26], a wide papillary opening due to adequate di-
lation after EPBD can facilitate stone removal and furthermore,
can reduce the need for lithotripsy. A sufficiently enlarged ori-
fice of the bile duct potentially eases insertion of endoscopic de-
vices and subsequent stone removal. However, we believe the
major advantage of EPBD is better long-term outcomes due to
the preserved function of the sphincter of Oddi. Therefore, a
large prospective study with longer follow-up data is warranted
to validate the role of long-duration EPBD in stone removal.
While the involvement of multiple endoscopists is advanta-
geous in terms of the generalizability of our data, the results
should be interpreted with caution. As we discussed above,
EPBD has been the major procedure used for stone extraction
in our centers until recently, and the attending physicians
were familiar with stone extraction procedures after EPBD.
Gentle manipulation of devices for stone extraction is manda-
tory to prevent ampullary edema and subsequent PEP after
EPBD because of the small opening of the ampulla. Endos-
copists who are used to stone extraction only after EST may
prefer 5-minute EPBD.
There are some limitations to be acknowledged in this study.
First, there were between-group differences in patient and pro-
cedural characteristics due to the retrospective nature of this
study. Inherent bias was still possible even after the multivari-
able analysis for the risk factors of PEP. A prospective RCT is
warranted to evaluate the superiority of 5-minute EPBD. Sec-
ond, there was a statistically significant difference in the ad-
ministration rate of NSAIDs between the groups (36.8% vs.
1.3% in the 5-minute and 15-second EPBD groups, respectively;
P<0.001). Controversy still exists with regard to the routine use
of NSAIDs [35], but at least no data have suggested that NSAIDs
adversely affect the safety or effectiveness of ERCP. In addition,
because 5-minute EPBD was introduced into clinical practice la-
ter than 15-second EPBD, the learning curve effects for the 5-
minute EPBD procedure should be considered. However, apart
from the duration time, the procedures could be carried out in
the same manner and therefore, we believe that the influence
of less expertise in 5-minute EPBD on our findings might be
minimal. Finally, the negative results of our study could have
been due to the relatively small sample size, although our sam-
ple size calculation supported the view that the size of our
study population might have been sufficient.
In conclusion, our study did not support the superiority of 5-
minute EPBD over 15-second EPBD in terms of prevention of
PEP. Although 5-minute EPBD appeared to facilitate complete
stone removal with less frequent use of lithotripsy and a smaller
number of ERCP sessions, further evidence is required before
implementing 5-minute EPBD in clinical practice.
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▶ Table 6 Multivariable analysis of risk factors for PEP.
Multivariable
OR 95%CI P value
5-minute EPBD 1.02 0.50– 1.99 0.948
Younger age (< 50 y) 1.04 0.39– 2.78 0.933
Pancreatic duct opacification 2.64 1.31– 5.29 0.006
Pancreatic stent 1.67 0.74– 3.75 0.216
CI, confidence interval; EPBD, endoscopic papillary balloon dilation; OR, odds ratio; PEP, post-ERCP pancreatitis.
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